{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:19:23Z","timestamp":1792210763874,"version":"4.4.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/ajg.2013.219","type":"journal-article","created":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T09:32:47Z","timestamp":1374571967000},"page":"1458-1463","source":"Crossref","is-referenced-by-count":300,"title":["A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy"],"prefix":"10.14309","volume":"108","author":[{"given":"Barjesh Chander","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish Kumar","family":"Lunia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210210","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy definition, nomenclature, diagnosis, and qualification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998.","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"key":"R2-14-20210210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy.","volume":"25","author":"Poordad","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R3-14-20210210","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis.","volume":"30","author":"Bustamante","year":"1999","journal-title":"J Hepatol"},{"key":"R4-14-20210210","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.1840160608","article-title":"The effect of oral administrated lactulose on colonic nitrogen metabolism and excretion.","volume":"16","author":"Mortensen","year":"1992","journal-title":"Hepatolgy"},{"key":"R5-14-20210210","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non absorbable diasacchardes for hepatic encephalopathy: systemic review of randomised trials.","volume":"328","author":"Als-Nielsen","year":"2004","journal-title":"BMJ"},{"key":"R6-14-20210210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.","volume":"3","author":"Gerard","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R7-14-20210210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1179\/joc.2008.20.2.186","article-title":"Effects of rifaximin on bacterial virulence mechanisms at supra and subinhibitory concentrations.","volume":"20","author":"Debbia","year":"2008","journal-title":"J Chemother"},{"key":"R8-14-20210210","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Nm, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy.","volume":"362","year":"2010","journal-title":"N Eng J Med"},{"key":"R9-14-20210210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"key":"R10-14-20210210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.","volume":"46","author":"Paik","year":"2005","journal-title":"Yonsei Med J"},{"key":"R11-14-20210210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.","volume":"38","author":"Mas","year":"2003","journal-title":"J Hepatol"},{"key":"R12-14-20210210","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rossellini SR et al Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double blind, randomised trial.","volume":"13","author":"Miglio","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"R13-14-20210210","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0b013e328302f470","article-title":"Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a metaanalysis.","volume":"20","author":"Jiang","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R14-14-20210210","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1592\/phco.28.8.1019","article-title":"Rifaximin for the treatment of hepatic encephalopathy.","volume":"28","author":"Lawrence","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R15-14-20210210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1345\/aph.1K436","article-title":"Rifaximin for treatment of hepatic encephalopathy.","volume":"43","author":"Maclayton","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R16-14-20210210","first-page":"57","article-title":"Rifaximin in the treatment of hepatic encephalopathy.","volume":"4","author":"Giacomo","year":"1993","journal-title":"Eur J Clin Res"},{"key":"R17-14-20210210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0011-393X(05)80681-2","article-title":"Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety.","volume":"54","author":"Festi","year":"1993","journal-title":"Curr Ther Res Clin Exp"},{"key":"R18-14-20210210","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3748\/wjg.v18.i8.767","article-title":"Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.","volume":"18","author":"Eltawil","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R19-14-20210210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy.","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"key":"R20-14-20210210","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01072921","article-title":"Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial.","volume":"23","author":"Atterbury","year":"1978","journal-title":"Am J Dig Dis"},{"key":"R21-14-20210210","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/j.1572-0241.2002.05791.x","article-title":"Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.","volume":"97","author":"Bauer","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R22-14-20210210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2010.05.017","article-title":"Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.","volume":"53","author":"Gupta","year":"2010","journal-title":"J Hepatol"},{"key":"R23-14-20210210","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12072-012-9360-9","article-title":"Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy.","volume":"7","author":"Lunia","year":"2013","journal-title":"Hepatol Int"},{"key":"R24-14-20210210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/17425250902973695","article-title":"Rifaximin pharmacology and clinical implication.","volume":"5","author":"Ojetti","year":"2009","journal-title":"Expert Opin Drug Meta Toxicol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2013219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2013219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2013219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201309000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:37Z","timestamp":1786542397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201309000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2013.219","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}